Screening Library definition

Screening Library shall have the meaning given in the first recital. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
View Source
Screening Library means the ▇▇▇▇▇ Compound Library or the Tularik Compound Library.
View Source
Screening Library means a chemical compound library, other than a Focused Library, comprising at least 108 distinct target structures, based on specific agreed scaffold(s) and synthons, prepared by DiCE for use in DiCE internal and external programs, including the Research Program.
View Source

Examples of Screening Library in a sentence

  • The Roche Bioscience Screening Library is not part of the Research Compound Library, but may, in Roche Bioscience's sole discretion, be used in HTS against the Targets.

  • The Roche Bioscience Screening Library shall be treated as Roche Bioscience's Confidential Information.

  • Title to and ownership of all Inventions directly related to the NeoMorph Screening Library, ALIS screening technology or QSCD (regardless of inventorship), as well as those Inventions subject to Section 3.5(b)(i) (hereinafter "NEOGENESIS INVENTIONS"), shall be the sole property of NeoGenesis and are included in NeoGenesis Know-How and/or NeoGenesis Patent Rights, as the case may be.

  • Derivatives made as part of a Collaboration Medicinal Chemistry Program from compounds originating from the Roche Bioscience Screening Library shall be considered part of the Roche Compound Library.

  • Subject to Section 5.5, Roche Bioscience hereby grants to Tularik a non-exclusive, royalty-bearing (in accordance with Section 9.5) license to use those compounds in the Roche Bioscience Screening Library to which Roche Bioscience permits Tularik access in Roche Bioscience's sole discretion, which license is solely for HTS and confirmation of "hits" during the Research Term in accordance with the Research Plan (the "Roche Bioscience Screening License").

  • The Tularik Screening Library shall be treated as Tularik's Confidential Information.

  • Derivatives made as a result of HTS as part of the Research Collaboration from compounds originating from the Roche Bioscience Screening Library shall be considered part of the Research Compound Library.

  • Derivatives made as a result of HTS as part of the Research Collaboration from compounds originating from the Tularik Screening Library shall be considered part of the Research Compound Library.

  • Except for the Tularik Screening License, Roche Bioscience shall have no rights to compounds originating from the Tularik Screening Library unless a Library Compound becomes a Development Compound under Section 5.2. Tularik shall provide structural information to Roche Bioscience on Validated Hits [ * ].

  • Structural information on compounds in the Roche Bioscience Screening Library that are not Validated Hits shall [ * ].